A sculpture outside of the CMS headquarters building in Baltimore, Md. The federal agency yesterday said it would continue a deep cut in 340B hospitals’ Medicare drug reimbursement in 2021. | Source: Wikipedia
340B Hospitals Face Another Year of Deeply Reduced Medicare Drug Reimbursement
The Trump administration last night announced that, in 2021, many hospitals’ Medicare Part B reimbursement for drugs bought through the 340B program will stay at the same deeply reduced rate it has been at since 2018—average sales price (ASP) minus 22.5 percent.
The U.S. Centers for Medicare & Medicaid Services (CMS) decided not to use an alternative reimbursement methodology that would have deepened the cut next year to an effective rate of ASP minus 28.7 percent. That rate would have been based on CMS’s controversial survey of hospitals this spring for their net costs for 340B-purchased drugs billed to Part B.
.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
×